Email: ir@altimmune.com
Search
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
August 19, 2025 - … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: …
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
August 12, 2025 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
Altimmune Board of Directors Appoints Jerry Durso as Chairman
August 11, 2025 - … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke, Biotech Phone: …
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
July 9, 2025 - … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: …
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
June 26, 2025 - … and ALD. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: …
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
May 19, 2025 - … (ALD). For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke, Biotech Phone: …
Altimmune Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … (ALD). For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
February 27, 2025 - … are available at https://investorday.altimmune.com . Additional information related to the event will be posted to this site. Corporate Update The Company strengthened its Board of … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, …
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
November 15, 2024 - … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Executive Officer Phone: 240-654-1450 ir@altimmune.com Media Contact: Danielle Cantey Inizio Evoke, Biotech Phone: 619-826-4657 Danielle.cantey@inizioevoke.com Investor Contact: Lee Roth Burns McClellan Phone: …
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
November 12, 2024 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … and MASH. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
